Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nano-crystalline megestrol acetate for cancer cachexia during neoadjuvant serplulimab + SOX in stage III gastric/GEJ adenocarcinoma
ChiCTR2600131569Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of megestrol in cancer anorexia-cachexia syndrome (CACS) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Proportion of subjects with weight increase relative to baseline during neoadjuvant therapy. Started May 2025; status: recruiting.
02
Drugs
megestrol
03
Conditions
cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on ChiCTR2600131569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131569.